Last Price
1.23
Today's Change
+0.296 (31.69%)
Day's Change
0.795 - 2.21
Trading Volume
131,613,694
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Hermann Luebbert Ph.D. Dr. Hermann Luebbert Ph.D.
Full Time Employees: 83 83
IPO Date: 2021-10-29 2021-10-29
CIK: 0001858685 0001858685
ISIN: US09077D2099 US09077D2099
CUSIP: 09077D100 09077D100
Beta: 0.51 0.51
Last Dividend: 0.00 0.00
Dcf Diff: 0.00 0.00
Dcf: 0.00 0.00
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.